Cargando…

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

The goal of this Phase I/II trial is to assess the safety and efficacy of administering durvalumab concurrent with weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide (ddAC) neoadjuvant therapy for stages I–III triple-negative breast cancer. The primary endpoint is pathologic complete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foldi, Julia, Silber, Andrea, Reisenbichler, Emily, Singh, Kamaljeet, Fischbach, Neal, Persico, Justin, Adelson, Kerin, Katoch, Anamika, Horowitz, Nina, Lannin, Donald, Chagpar, Anees, Park, Tristen, Marczyk, Michal, Frederick, Courtney, Burrello, Trisha, Ibrahim, Eiman, Qing, Tao, Bai, Yalai, Blenman, Kim, Rimm, David L., Pusztai, Lajos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870853/ https://www.ncbi.nlm.nih.gov/pubmed/33558513 http://dx.doi.org/10.1038/s41523-021-00219-7

Ejemplares similares

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
por: Marczyk, Michal, et al.
Publicado: (2022)

Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
por: Dieli-Conwright, Christina M., et al.
Publicado: (2022)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
por: Mani, Nikita L., et al.
Publicado: (2016)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
por: Kunst, Natalia, et al.
Publicado: (2020)

Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study
por: Yaghoobi, Vesal, et al.
Publicado: (2021)

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Smoking and Breast Cancer Recurrence after Breast Conservation Therapy
por: Bishop, Jennifer D., et al.
Publicado: (2014)

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
por: Fanucci, Kristina A., et al.
Publicado: (2023)

Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database
por: Plasilova, Magdalena L., et al.
Publicado: (2016)

Sociodemographic factors affecting telemedicine access: A population-based analysis
por: Chagpar, Anees B.
Publicado: (2022)

The impact of virtual negotiation training for female faculty
por: Chagpar, Anees B.
Publicado: (2023)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
por: Morgensztern, Daniel, et al.
Publicado: (2021)

Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience
por: Berrocal, Julian, et al.
Publicado: (2017)

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
por: Renouf, Daniel J., et al.
Publicado: (2022)

HPV vaccination and factors influencing vaccine uptake among people of Indian ancestry living in the United States
por: Ratnasamy, Philip, et al.
Publicado: (2022)

Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
por: Patwardhan, Gauri A., et al.
Publicado: (2021)

The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients
por: Trant, Amelia A., et al.
Publicado: (2022)

Diverse immune response of DNA damage repair-deficient tumors
por: Qing, Tao, et al.
Publicado: (2021)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
por: Pelekanou, Vasiliki, et al.
Publicado: (2018)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity
por: Shi, Weiwei, et al.
Publicado: (2018)

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
por: Foldi, Julia, et al.
Publicado: (2023)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Association between low estrogen receptor positive breast cancer and staining performance
por: Caruana, Dennis, et al.
Publicado: (2020)

Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
por: Zyla, Joanna, et al.
Publicado: (2023)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Phimosis: A rare complication of immunotherapy with durvalumab
por: Vázquez-Lavista, Luis Gabriel, et al.
Publicado: (2020)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
por: Patel, Shivani, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1aup73bmb6402chutinjb6r67i